Skip to main content

Table 4 Pharmacokinetic parameters following nebulization of voriconazole (VRC) and its lipid-polymer hybrid nanoparticles (LPH NPs)

From: Nebulised surface-active hybrid nanoparticles of voriconazole for pulmonary Aspergillosis demonstrate clathrin-mediated cellular uptake, improved antifungal efficacy and lung retention

Parameter(s)

Lung pharmacokinetics

Plasma pharmacokinetics

VRC solution

VRC LPH NPs

VRC solution

VRC LPH NPs

Cmax (μg mL−1)

13.43 ± 3.10

26.29 ± 5.78

6.81 ± 1.11

7.79 ± 2.07

Tmax(h)

0.17 ± 0.00

0.67 ± 0.29

0.39 ± 0.19

1.67 ± 0.38

AUC0-24 (μg mL−1*h)

36.38 ± 5.40

177.75 ± 23.40

33.89 ± 5.05

69.01 ± 10.25

AUC0-∞ (μg mL−1*h)

41.77 ± 6.75

237.51 ± 22.98

35.94 ± 6.11

89.16 ± 16.71

MRT (h)

5.27 ± 1.31

16.46 ± 2.87

7.13 ± 1.03

15.26 ± 3.44

  1. Data expressed as mean ± SD (n = 3)
Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us